Enantioselective synthesis of PPAR (peroxisome proliferator-activated receptors) agonists and antagonists.
This review deals with stereoselective issues in PPAR ligands some of which are in clinical use for treating certain metabolic disorders. After a short introduction of these nuclear receptor and their agonists, some cases of enantioselective separations are reported. The main part concerns stereoselective synthesis first starting with asymmetric synthesis from chiral precursors followed by what we refer to as "true" enantioselective methods. Some examples are discussed in detail for each particular heading.
Pilar
P
Goya
Ruth
R
Perez-Fernandez
Rosario
R
Gonzalez-Muniz
Instituto de Quimica Medica, Juan de la Cierva 3, 28006 Madrid, Spain. pgoya@iqm.csic.es.
Jose
J
Elguero
D060326:Chemistry Techniques, Synthetic; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors